Biotech & Pharmaceuticals

Arena Pharmaceuticals’ drug Ralienpag met its Phase 2 program goals.

Lilly says the FDA needed additional data to “characterize safety concerns across treatment arms.”

While the White House and Congress struggled to repeal Obamacare, investors did not shy away from health-care stocks in the first quarter.

United Therapeutics said it would be delaying the launch of an implantable pump until 2018.

The track record in drug development for Alzheimer’s disease has been terrible: a success rate of less than 1 percent.

Almost 200,000 people have fatally overdosed on opioids in the past 15 years, with more than 30,000 people dying in 2015 alone.

Traders are worried that Repatha isn’t effective enough to justify the drug’s hefty price tag of over $14,500 per year.

The drug, known as JCAR015, was being tested in adults with relapsed acute lymphoblastic leukemia, a rare and deadly blood cancer.

Express Scripts said despite the double-digit increase, costs for employers rose just 2.5 percent across all prescription drugs.

More than $125 million has been spent over an initiative to bar state agencies from paying more for drugs than the Veterans Affairs Department pays.

Price increases on life-saving EpiPens have parents outraged — but the CEO of the company that makes them said no one’s more frustrated than her.

With biotech stocks at their highest level since January, one strategist thinks a Donald Trump presidential win could send them even higher.

Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.

Meg Tirrell explains what to look for in the biotech industry in 2016.